Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hyperin
2. Quercetin Galactoside
3. Quercetin-3-o-galactoside
1. 482-36-0
2. Hyperin
3. Quercetin 3-galactoside
4. Hyperosid
5. Hyperozide
6. Quercetin-3-o-galactoside
7. Quercetin-3-galactoside
8. Quercetin 3-d-galactoside
9. Hyperasid
10. Jyperin
11. Quercetin 3-o-beta-d-galactopyranoside
12. Quercetin 3-beta-d-galactopyranoside
13. Quercetin 3-o-galactoside
14. Nsc 407304
15. Chembl251254
16. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
17. Chebi:67486
18. 8o1cr18l82
19. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
20. Quercetin 3-.beta.-d-galactopyranoside
21. 2-(3,4-dihydroxyphenyl)-3-(beta-d-galactopyranosyloxy)-5,7-dihydroxy-4h-1-benzopyran-4-one
22. 4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-d-galactopyranosyloxy)-5,7-dihydroxy-
23. Quercetin Galactoside
24. 2-[3,4-bis(oxidanyl)phenyl]-3-[(2s,3r,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one
25. Quercetin 3-b-d-galactoside
26. Mfcd00016933
27. Unii-8o1cr18l82
28. Ccris 9339
29. P Hyperin
30. Quercetin 3-o-beta-d-glucopyranoside
31. Nsc-407304
32. Quercetin 3-o-.beta.-d-galactopyranoside
33. Hyperin,(s)
34. Einecs 207-580-6
35. Hyperoside [usp-rs]
36. Bidd:pxr0057
37. 3,3',4',5,7-pentahydroxyflavone 3-d-galactoside
38. Mls000759538
39. 2-yloxy)-4h-chromen-4-one
40. Jm5b01461, Compound 84
41. Megxp0_000392
42. Schembl1250514
43. Acon1_000623
44. Quercetin 3-o-beta-d-galactoside
45. Bdbm429266
46. Dtxsid501028789
47. Hms2051h17
48. Hy-n0452
49. Quercetin 3-o--d-galactopyranoside
50. Zinc3973253
51. Bdbm50241367
52. S5453
53. Akos015896780
54. 6-(hydroxymethyl)tetrahydro-2h-pyran-
55. Ccg-100970
56. Nc00220
57. Ncgc00168902-03
58. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one
59. As-56199
60. Smr000466394
61. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
62. Quercetin 3-o-.beta.-d-galactoside
63. Cs-0008982
64. N1838
65. Quercetin 3-d-galactoside, >=97.0% (hplc)
66. Ab00639910-03
67. 3-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-
68. 482h360
69. Hyperoside, Primary Pharmaceutical Reference Standard
70. Q-100530
71. Q5242815
72. Brd-k84955386-001-01-1
73. 3-o-b-d-galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone
74. Hyperoside (constituent Of St. John's Wort) [dsc]
75. Hyperoside, United States Pharmacopeia (usp) Reference Standard
76. Hyperoside (constituent Of Hawthorn Leaf With Flower) [dsc]
77. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-chromen-3-yl Beta-d-galactopyranoside
78. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-chromen-3-yl Hexopyranoside #
79. 2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-3-((2s,4r,5r)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one
80. 2-(3,4-dihydroxyphenyl)-3-(.beta.-d-galactopyranosyloxy)-5,7-dihydroxy-4h-1-benzopyran-4-one
81. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
82. 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4h-chromen-4-one
83. 4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(beta-d-galactopyranosyloxy)-5,7-dihydroxy-
84. J6o
| Molecular Weight | 464.4 g/mol |
|---|---|
| Molecular Formula | C21H20O12 |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 4 |
| Exact Mass | 464.09547607 g/mol |
| Monoisotopic Mass | 464.09547607 g/mol |
| Topological Polar Surface Area | 207 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 758 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Hyperoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyperoside, including repackagers and relabelers. The FDA regulates Hyperoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyperoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Hyperoside supplier is an individual or a company that provides Hyperoside active pharmaceutical ingredient (API) or Hyperoside finished formulations upon request. The Hyperoside suppliers may include Hyperoside API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyperoside as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hyperoside API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hyperoside as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hyperoside and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyperoside NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hyperoside suppliers with NDC on PharmaCompass.
Hyperoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hyperoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyperoside GMP manufacturer or Hyperoside GMP API supplier for your needs.
A Hyperoside CoA (Certificate of Analysis) is a formal document that attests to Hyperoside's compliance with Hyperoside specifications and serves as a tool for batch-level quality control.
Hyperoside CoA mostly includes findings from lab analyses of a specific batch. For each Hyperoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hyperoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyperoside EP), Hyperoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyperoside USP).
LOOKING FOR A SUPPLIER?
